DATASET RE-READ 2026-11-2042 PROGRAMSNEXLIFE PRICES READ 2026-11-20EVERY FIGURE CARRIES ITS READ DATE
TopGLP1Providers.comverified price index
DATED PRICES

MEDVi vs ShedRx: November 2026 prices compared

As of November 20, 2026, neither MEDVi nor ShedRx printed a month-to-month compounded price that applies at the maintenance dose, so this page compares what each did show and how each bills, without a price verdict.

Released · Last reviewed · how we verify

MEDVi and ShedRx, measure by measure

MEDVi and ShedRx side by side, from each program’s own page read November 20, 2026 (all-in: medication plus any required recurring fee, before tax)
MeasureMEDViShedRx
Tirzepatide, month to month—from $239 (lowest printed: "starting as low as"; no month-to-month figure)
Tirzepatide, lowest printed—$239 ("starting as low as")
Semaglutide, month to month—from $159 (lowest printed: "GLP-1s from $159/mo" (drug not named); no month-to-month figure)
Semaglutide, lowest printed—$159 ("GLP-1s from $159/mo" (drug not named))
Dose pricingnot confirmedpriced by dose or not stated
Membership or program feenot confirmednone
Computed score0 of 40 (position 21 of 27)12 of 40 (position 16 of 27)
FDA warning letters721455 (2026-02-20)none listed
November 20 readnot readable Nov 20first-party read

Strengths and limitations: which fits whom

MEDVi cannot be judged on price this month because its page could not be read on November 20, 2026. ShedRx prints a month-to-month price; confirm whether it changes with the dose before you rely on it for a year. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.

What changed since August

The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.

What changed since the August 2026 capture (maintenance-dose all-in figure then; month-to-month all-in figure read November 20, 2026)
ProgramMedicationAugust 5–10, 2026November 20, 2026
ShedRxtirzepatide—from $239
ShedRxsemaglutide—from $159

Regulatory record

FDA’s warning-letter index lists warning letter 721455 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to MEDVi; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.

Check MEDVi’s current prices ↗
Check ShedRx’s current prices ↗

Frequently asked

Which is cheaper, MEDVi or ShedRx?

Neither printed a comparable month-to-month price on November 20, 2026, so there is no like-for-like answer this month.

Do MEDVi and ShedRx charge a membership fee?

MEDVi: not confirmed on November 20, 2026; ShedRx: no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.

Are MEDVi and ShedRx medications FDA-approved?

Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.

MEDVi recordMEDVi alternativesShedRx recordShedRx alternativesAll head-to-headsRankingsPrice database

Sources

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.